

Genomics to Health

Institute of Medicine

Roundtable on

Translating Genomic-Based Research for Health

December 3, 2012

Edison Liu, M.D.

The Jackson Laboratory

Edison Liu, M.D.
The Jackson Laboratory

I am a member of the Scientific Advisory Board for
a diagnostics company,
Veracyte
(San Francisco)

Acknowledgement

Central Observation:

US biomedical research has led the world

Our management of public domain science is being emulated throughout the world

Independent

peer review

Translational

biotech

Bayh Dole

Overhead recovery

**However, times are changing
The medical sciences have advanced
Expectations have escalated
The economics are different**


re &

Our focus was correct:

Vannevar Bush → Basic sciences

NIH → conquering disease

Facilitating commercialization



What is the difference?

**Cost of doing meaningful
biomedical research
is now high**

Biomedical Research and development Price Index:
Has exceeded GDP index every year
Has over tripled between since 1980, doubled
since 1990

Source NIH: [http:](http://officeofbudget.od.nih.gov/pdfs/FY12/BRDPI%20Table%20of%20Annual%20Values_05_18_2011.pdf)

[//officeofbudget.od.nih.gov/pdfs/FY12/BRDPI%20Table%20of%20Annual%20Values_05_18_2011.pdf](http://officeofbudget.od.nih.gov/pdfs/FY12/BRDPI%20Table%20of%20Annual%20Values_05_18_2011.pdf)

What is Different?

**Genomic
Technologies**

**Computational
Analytics**

**Combinatorial
Chemistry**

**Mature
Research Support
Infrastructure**

Scale



Spinning wheel

Cotton Gin



Let's be provocative

Central Premise:

Public/Academic Biomedical Research enterprise is inefficient relative to the technologies available

New mindset is needed

- Mission oriented research by collectives of like-minded scientists

- Milestone sensitive

- Attention to more efficient research processes

- Focusing on cost effective outcomes

New management approaches are required:

- Quality project management, expert project managers

- Strategic attention


- Expert review vs. peer review

We are pretty inefficient

Spending on drug, biotechnology and medical device research over doubled from \$37.1 billion in 1994 to \$94.3 billion in 2003.

Journal of the American Medical Association [Moses, H et al. Financial Anatomy of Biomedical Research. JAMA 2005;294-1333-1342](#)

But...



Inefficient despite the power of current science:

Case studies

- Ph1 chromosome identified 1960 as a marker for CML (Nowell)
- bcr-abl cloned and shown to be the molecular mechanism 1984-1990 (Groffen and Lugo)
- Specific drug (Gleevec) to target gene abnormality 1999 (Druker)

From discovery of a single oncogene to treatment: 39 years


Identification of the transforming *EML4-ALK* fusion gene in non-small-cell lung cancer

Nature 2007



Manabu Soda^{1,2}, Young Lim Choi¹, Munehiro Enomoto^{1,2}, Shuji Takada¹, Yoshihiro Yamashita¹, Shunpei Ishikawa⁵, Shin-ichiro Fujiwara¹, Hideki Watanabe¹, Kentaro Kurashina¹, Hisashi Hatanaka¹, Masashi Bando², Shoji Ohno², Yuichi Ishikawa⁶, Hiroyuki Aburatani^{5,7}, Toshiro Niki³, Yasunori Sohara⁴, Yukihiko Sugiyama² & Hiroyuki Mano^{1,7}

In 2007, the genomic analysis of one lung cancer from a 62 year-old smoker
→ EML-ALK fusion in 6% of lung cancer patients





Crizotinib (PF-02341066)




Crizotinib → 60% response rate in those 6% of patients with lung cancer with the EML-ALK mutation.

On August 26, 2011, the US FDA gave approval of crizotinib by for the treatment of *ALK*-rearranged lung cancer

4 years from genomic discovery to treatment

Cost of sequencing a human genome



Let's be provocative

Central Premise:

Public/Academic Biomedical Research enterprise is inefficient relative to the technologies available

New mindset is needed (changing cultures)

Mission oriented research by collectives of like-minded scientists

Milestone sensitive

Attention to more efficient research processes

Focusing on cost effective outcomes

New management approaches are required:

Quality project management, expert project ma

Strategic attention

Expert review vs. peer review

Examples

Energy Biosciences Institute (EBI): \$500 million over 10 years, sponsored by BP. UC Berkeley and University of Illinois CU

Janelia Farm: Diverse skills, common focus, freedom to explore, science as a social enterprise (patterned after Bell Labs)

Genome Institute of Singapore: \$300 million over 10 years. Diverse skills, Collective decision making, integrated platforms

Liu ET. Integrative biology - a strategy for systems biomedicine. Nat Rev Genet. 2009 Jan;10(1):64-8.

Examples: Focus on cost effective outcomes

Diagnostics as a systems optimizer

The Jackson Laboratory for Genomic Medicine and medical insurers:

Direct us to the clinical cancer problem that not only is a health problem but is also most costly to the health system. Could we derived a genomic solution for this indication?


Veracyte: Afirma Thyroid FNA diagnosis

(I am on Veracyte's Scientific Advisory Board)

Future scenario for Genomic Medicine:

- **All children with developmental disorders will be sequenced**
- **All cancers will be sequenced**
- **Whole Genome solutions are more cost effective than multiple single test**
- **Medical analytics in a secure and honest broker environment will be important**
- **All these efforts should improve cost effectiveness of delivering health care**


**Harnessing Genetic
Complexity:
Systems Genomics**




***Reconstructing the
Mouse Genome:
Tunable Mouse Models***



**Solutions to
Treating Human
Disease and to
Sustaining Health**



**Molecular
Mechanisms of
Disease**



Let's be provocative

Central Premise:

Public/Academic Biomedical Research enterprise is inefficient relative to the technologies available

New mindset is needed

Mission oriented research by collectives of like-minded scientists

Milestone sensitive

Attention to more efficient research processes

Focusing on cost effective outcomes

New management approaches are required:

Quality project management, expert project managers

Venture, DARPA


Strategic attention

Horizon scanning, advocacy

Expert review vs. peer review

HHMI vs. NIH study section

Emerging Demands in Biomedical Sciences



Emerging Demands in Biomedical Sciences

Research Realities – who will succeed:

Those who execute with speed

Those who are flexible

Those who can scale or have access to massively scaled capabilities

Those who can assemble functional teams quickly

Those with quality scientific managers

Those who can quickly embrace new and powerful technologies

Those who can understand and harness genetic complexity

Those who achieve direct relevance to human health

Genomics to Health

Institute of Medicine

Roundtable on

Translating Genomic-Based Research for Health

December 3, 2012

Edison Liu, M.D.

The Jackson Laboratory

